Related Experiment Video

Updated: Jul 20, 2026

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Mcl-1 is a relevant molecular target for antisense oligonucleotide strategies in gastric cancer cells

Volker Wacheck1, Daniel Cejka, Wolfgang Sieghart

  • 1Department of Clinical Pharmacology, Section of Experimental Oncology/Molecular Pharmacology, Medical University Vienna, Vienna, Austria. volker.wacheck@meduniwien.ac.at

Cancer Biology & Therapy
|September 14, 2006
PubMed

Insights

Targeting Mcl-1 protein in gastric cancer with antisense oligonucleotides significantly reduced cancer cell growth and increased apoptosis. Combining Mcl-1 antisense oligonucleotides with chemotherapy showed synergistic anti-tumor effects, suggesting a promising new treatment strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Gastric cancer is a leading cause of cancer mortality globally, often exhibiting resistance to chemotherapy.
  • The anti-apoptotic Mcl-1 protein is overexpressed in up to 75% of gastric cancers, correlating with poor patient prognosis.
  • The precise biological role and therapeutic potential of Mcl-1 in gastric cancer remain incompletely understood.

Purpose of the Study:

  • To investigate the functional importance of Mcl-1 in gastric cancer.
  • To evaluate Mcl-1 as a potential molecular target for therapeutic intervention using an antisense oligonucleotide (ASO) strategy.
  • To assess the efficacy of Mcl-1 ASO, alone and in combination with standard chemotherapies, in gastric cancer cell lines.

Main Methods:

  • Gastric cancer cell lines (NCI-N87, MKN-28, MKN-45) were treated with Mcl-1 antisense oligonucleotides.
  • Mcl-1 protein expression levels were quantified following treatment.
  • Cell proliferation and apoptosis assays were performed to assess anti-tumor effects.
  • Combination treatments with docetaxel or cisplatin were evaluated for synergistic activity.

Main Results:

  • Mcl-1 ASO treatment achieved approximately 50% reduction in Mcl-1 protein levels across all tested gastric cancer cell lines.
  • Downregulation of Mcl-1 by ASOs significantly induced apoptosis and reduced cancer cell growth by up to 60%.
  • Combination therapy involving Mcl-1 ASO and either docetaxel or cisplatin demonstrated synergistic anti-tumor effects.

Conclusions:

  • Mcl-1 antisense oligonucleotides exhibit significant single-agent anti-tumor activity in gastric cancer models.
  • Mcl-1 ASOs show synergistic effects when combined with conventional chemotherapeutic agents like docetaxel and cisplatin.
  • Mcl-1 represents a promising molecular target for developing novel antisense oligonucleotide-based therapies for gastric cancer.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...